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Abstract
Background: Incident hemodialysis patients have a high 
mortality risk within the first months after dialysis initiation. 
Pre-end-stage renal disease (ESRD) factors like anemia man-
agement may impact early post-ESRD outcomes. Therefore, 
we evaluated the impact of pre-ESRD hemoglobin (Hgb) and 
pre-ESRD Hgb slope on post-ESRD mortality and hospitaliza-
tion outcomes. Methods: The study included 31,472 veter-
ans transitioning to ESRD. Using Cox and negative binomial 
regression models, we evaluated the association of pre-
ESRD Hgb and Hgb slope with 12-month post-ESRD all-cause 
and cardiovascular mortality and hospitalization rates using 
4 levels of hierarchical multivariable adjustment, including 
erythropoietin use and kidney decline in slope models. Re-
sults: The cohort was 2% female, 30% African-American, and 
on average 68 ± 11 years old. Compared to Hgb 10–< 11 g/
dL, both low (< 10 g/dL) and high (≥12 g/dL) levels were as-
sociated with higher all-cause mortality after full adjustment 
(HR 1.25 [95% CI 1.15–1.35] and 1.09 [95% CI 1.02–1.18], re-
spectively). Similarly, Hgb exhibited a U-shaped association 
with CV mortality, while only lower Hgb was associated with 
a higher hospitalization rate. Neither an annual pre-ESRD de-
cline in Hgb nor increase was associated with higher post-
ESRD mortality risk after adjustment for kidney decline. How-
ever, we observed a modest J-shaped association between 
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pre-ESRD Hgb slope and post-ESRD hospitalization rate. 
Conclusions: Lower and higher pre-ESRD Hgb levels are as-
sociated with a higher risk of early post-ESRD mortality, 
while there was no association between the pre-ESRD slope 
and mortality. An increase in pre-ESRD Hgb slope was associ-
ated with higher risk of post-ESRD hospitalization. Addition-
al studies aimed at anemia management prior to ESRD tran-
sition are warranted. © 2018 S. Karger AG, Basel
Introduction
Anemia, a commonly observed condition in patients 
with chronic kidney disease (CKD), is strongly related to 
poorer outcomes, such that prior studies have demon-
strated its relationship with higher risk of all-cause and 
cardiovascular (CV) mortality, as well as hospitalization 
[1–3]. The prevalence of anemia progressively increases 
with the severity of CKD, ranging from 27% in stage 1/2 
CKD patients to 76% in stage 5 CKD patients due to the 
drastic reduction in renal erythropoietin production [4]. 
The current guidelines [5] specify that erythropoietin 
stimulating agent (ESA) therapy in dialysis patients should 
be initiated to avoid hemoglobin (Hgb) levels <9.0 g/dL, 
while for non-dialysis dependent CKD patients ESA ther-
apy should be individualized depending on the rate of Hgb 
decline if levels are below 10.0 g/dL. When individualizing 
ESA therapy in CKD patients, benefits such as potential 
reduction of blood transfusions should be weighed against 
risks such as hypertension, stroke, or vascular access loss. 
Additional potential benefits from correcting anemia may 
also include delaying progression of CKD [6], leading to a 
regression of left ventricular hypertrophy [7–9] and im-
provement in patients’ quality of life [10, 11]. Fink et al. 
[12] studied the impact of ESA administration prior to 
dialysis on post-dialysis initiation survival and found that 
pre-dialysis ESA was associated with lower mortality risk 
during the first 19 months after transition. In a cohort of 
patients on ESA therapy prior to dialysis initiation, Kata-
oka et al. [13] reported that Hgb levels below 8 g/dL at the 
time of hemodialysis initiation were associated with a 
higher incidence of CV and cerebrovascular events com-
pared to Hgb levels ≥8 g/dL. Although a meta-analysis of 
several studies has cautioned that treating to “normalized” 
Hgb ranges may not improve survival [14] and that a rap-
id increase in Hgb levels in a short period of time may also 
lead to adverse outcomes [15, 16], a rapid decline in Hgb 
has also been associated with higher risk of mortality and 
CV events [17].
To date, there are no studies that have investigated as-
sociations of both Hgb levels and its changes (slope) prior 
to ESRD initiation with post-ESRD outcomes. Thus, we 
sought to examine the association of pre-ESRD Hgb val-
ues and Hgb changes expressed as slope with early post-
ESRD hospitalization rate, CV, and all-cause mortality in 
a contemporary cohort of veterans. 
Methods
Study Population and Data Source
The analytical cohort was derived from the United States Renal 
Data System (USRDS) Special Study Center Transition of Care in 
CKD, which aimed to investigate incident ESRD US veterans who 
transitioned to ESRD between October 1, 2007 and March 30, 2014 
[18–23]. Of the original population of 85,505 veterans derived 
from USRDS records, we excluded patients without data on fol-
low-up (n = 1,958) and with missing date of birth (n = 3). Finally, 
we excluded 52,072 patients who did not have Hgb measured in 
the 6 months prior to the transition to ESRD. Thus, our final ana-
lytical cohort consisted of 31,472 incident ESRD patients (online 
suppl. Fig. S1; for all online suppl. material, see www.karger.com/
doi/10.1159/000489223). In additional analysis examining the as-
sociation of pre-ESRD Hgb slopes with outcomes, we further ex-
cluded an additional 6,773 patients who did not meet the slope 
criteria of ≥2 Hgb measurements at least 90 days apart during the 
1-year pre-ESRD (prelude) period, thereby resulting in an ana-
lytical sub cohort of 24,699 patients. Given the nonintrusive na-
ture, patient anonymity, and large sample size, the requirement for 
written informed consent was waived and the study was approved 
by the Memphis and Long Beach Veterans Affairs (VA) Medical 
Centers Institutional Review Boards.
Demographic, Clinical, and Laboratory Measurements
Patient characteristics collected at baseline were extracted from 
a composite of USRDS, VA, and Centers for Medicare and Medic-
aid Services (CMS) databases. Data on marital status were ob-
tained from the VA records only. Data on the primary cause of 
ESRD and access type at dialysis initiation were collected from 
USRDS records only. VA and CMS data were used to determine 
the preexisting comorbidity status and Charlson Comorbidity In-
dex (CCI). Prescription medication information was extracted 
from CMS Medicare Part D and VA pharmacy dispensation re-
cords. Medication use in this study was defined as ever having a 
prescription filled during the baseline period, 6 months prior to 
ESRD transition. 
Most laboratory measurements, including serum Hgb, were 
obtained from the VA Decision Support System National Data Ex-
tracts Laboratory Results file. Serum ferritin was extracted from 
the VA Corporate Data Warehouse (CDW) LabChem file. Data on 
serum creatinine were chiefly extracted from USRDS records of 
the CMS 2728 form, and supplemented with data from the VA 
CDW LabChem file. Estimated glomerular filtration rate (eGFR) 
at transition was calculated from serum creatinine according to the 
Chronic Kidney Disease Epidemiology Collaboration equation 
[24]. Finally, body mass index (BMI) and blood pressure data were 
obtained from the VA CDW Vital Signs file. With the exception of 
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the last eGFR prior to transition, all laboratory measurements dur-
ing the 6-month period prior to ESRD transition were averaged 
into a single measurement and used as baseline levels. Kidney 
function decline, expressed by eGFR slope, was calculated using a 
mixed-effects (random intercept and slope) model in patients with 
≥2 eGFR measurements at least 90 days apart during the 1-year 
pre-ESRD period, and included at least one measurement in the 
6-month prelude period [21]. 
Exposure Measurement
The main exposure of this study was pre-ESRD (prelude) Hgb. 
Baseline prelude Hgb levels were averaged over 6 months prior to 
transition and were categorized into 5 groups: (1) < 9.0, (2) 9.0–< 
10.0, (3) 10.0–< 11.0, (4) 11.0–< 12.0, and (5) 12 or more g/dL. 
Among a subset of these patients, we also calculated the Hgb slope 
over the 1-year period prior to transition using a mixed-effects mod-
el. We then categorized Hgb slope into 5 groups: (1) ≤–3.0, (2) >–3.0 
to ≤–2.0, (3) >–2.0 to ≤–1.0, (4) >–1.0 to ≤0, and (5) > 0 g/dL/year. 
Outcome Assessment
The main outcomes of interest were post-ESRD 12-month all-
cause mortality, 12-month CV mortality, and 12-month hospital-
ization rate. CV causes of death were extracted from USRDS re-
cords. Information on all outcomes and censoring events were ob-
tained from VA, CMS, and USRDS records. Patients were followed 
from the initiation of ESRD and until death, kidney transplanta-
tion, loss to follow-up, or the date of final follow-up for all patients 
(12 months post-ESRD or September 2, 2014 for all-cause mortal-
ity and June 30, 2014 for CV mortality). 
Statistical Analysis
Patient demographic and clinical characteristics are presented 
as means ± SD, median (interquartile range [IQR]), or percent as 
appropriate for the total cohort and stratified by Hgb groups.
To examine trajectories of monthly averaged Hgb 1-year pre- 
and post-transition, we used a mixed-effects regression model and 
stratified trajectories by the baseline Hgb group. 
Cox proportional hazard models were used to evaluate the as-
sociation of Hgb (baseline, or slope) with all-cause and CV mortal-
ity. Finally, the relationship of Hgb (baseline, or slope) with 
12-month hospitalization rates was evaluated using negative bino-
mial regression models. 
For each outcome, 4 hierarchal models of adjustment were 
used: (i) unadjusted; (ii) case-mix: age, gender, race, ethnicity, 
marital status, CCI, atrial fibrillation, hyperlipidemia, ischemic 
heart disease, myocardial infarction, congestive heart failure, pe-
ripheral vascular disease, cerebrovascular disease, chronic ob-
structive pulmonary disease, peptic ulcer disease, liver disease, di-
abetes mellitus, cancer, and primary cause of ESRD; (iii) case-
mix  + malnutrition inflammation complex syndrome (MICS): 
which included all covariates in the case-mix model plus last eGFR 
prior to transition and baseline laboratory measures of bicarbon-
ate, albumin, calcium, phosphorus, white blood cell count, alkaline 
phosphatase, BMI, and ever use of oral or intravenous (IV) iron 
and ESA in the 6-month pre-ESRD period. For the slope analyses, 
we further adjusted for the last available Hgb measurement in the 
1-year period prior to ESRD transition as a covariate in all models. 
Finally, an additional model (iv) was included in slope analyses, 
which adjusted for covariates from the case-mix and MICS model 
with further adjustment for eGFR slope. 
We defined the case-mix + MICS adjustment and the case-mix 
+ MICS + last Hgb + eGFR slope adjustment as the primary mod-
els of interest for the baseline and slope analyses respectively. In 
sensitivity analyses, we examined the baseline Hgb-mortality rela-
tionship in subgroup analyses across strata of clinical characteris-
tics, and in analyses modeling Hgb and Hgb slope as a continuous 
variable using restricted cubic splines with knots at the 5th, 35th, 
65th, and 95th percentiles. 
There were < 0.2 and 3% of missing data on demographics and 
medications, respectively, and were handled using missing catego-
ries. Laboratory measurements used in analyses were missing on 
an average, 13% of the patients and were imputed with means. All 
analyses were conducted using SAS Enterprise Guide, version 7.1 
(Cary, NC, USA) and STATA version 14.2 (StataCorp, College Sta-
tion, TX, USA). 
Results
Baseline Demographic, Clinical, and Laboratory 
Characteristics
A total of 31,472 US veterans transitioning to ESRD 
were included in this study. The cohort was on average 
68  ± 11 years old and included 2% female and 30% 
 African-American patients, as well as 47% patients with 
diabetes mellitus as the primary cause of ESRD and 69% 
who initiated ESRD with a central venous catheter (Table 
1). In the 6 months prior to transition to ESRD, patients 
had a (mean ± SD) Hgb of 10.6 ± 1.6 g/dL. Patients with 
lower Hgb were more likely to be younger, African-
American and not married; and had lower prevalence of 
CV disease including myocardial infarction, congestive 
heart failure, peripheral vascular disease, ischemic heart 
disease, and cerebrovascular disease (Table 1). Moreover, 
lower Hgb patients were more likely to have lower levels 
of BMI, serum bicarbonate and calcium, yet higher mea-
surements of blood urea nitrogen and systolic blood pres-
sure. Finally, patients with a low level of Hgb were more 
likely to have prescriptions for ESA and oral or IV iron in 
the 6-months prior to transition. 
6-Month Averaged Pre-ESRD Hgb and 12-Month 
Post-ESRD Mortality 
During the first 12-months of ESRD, 7,198 patients 
died with a crude rate of 27.5 deaths (26.9, 28.2) per 100 
person-years. Patients with Hgb 10–< 11 g/dL had the 
lowest rate of 12-month all-cause mortality. After adjust-
ment for demographics and comorbid conditions, there 
was a U-shaped association between baseline Hgb and 
12-month all-cause mortality (reference Hgb 10–< 11 g/
dL; online suppl. Table 1a; Fig. 1a). Moreover, after ad-
justment for laboratory parameters as well as medica-
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Table 1. Baseline characteristics of 31,472 veterans transitioning to ESRD stratified by 6-month pre-ESRD hemoglobin
Total 6-Month pre-ESRD Hgb strata, g/dL
<9 9–<10 10–<11 11–<12 ≥12
n (%) 31,472 4,637 (14.8) 7,342 (23.3) 8,078 (25.7) 5,705 (18.1) 5,710 (18.1)
Demographics
Age, years 68±11 65±11 68±11 69±11 69±11 69±11
Gender, %
Female 2 2 2 2 2 1
Race, %
White 65 48 60 66 71 77
African-American 30 47 34 29 25 19
Other 5 5 5 5 5 4
Ethnicity, %
Hispanic 8 8 8 8 7 7
Marital status, %
Single 9 13 9 8 7 7
Married 53 43 51 55 57 59
Divorced 27 34 29 26 25 25
Widowed 11 10 11 11 10 10
Primary cause of ESRD, %
Diabetes 47 47 50 49 46 39
Hypertension 28 26 26 29 30 30
Glomerulonephritis 6 6 6 6 6 6
Cystic kidney disease 1 1 1 1 2 2
Other/unknown cause 18 20 17 15 16 22
Charlson comorbidity index 4 (2–5) 3 (2–5) 4 (2–5) 4 (2–5) 4 (2–6) 3 (2–5)
Comorbid conditions, %
Anemia 69 77 77 74 68 50
Atrial fibrillation 14 10 14 14 15 17
Depression 26 26 27 25 25 25
Hyperlipidemia 78 69 77 80 81 81
Ischemic heart disease 54 44 53 56 57 58
Myocardial infarction 23 16 22 24 25 27
Congestive heart failure 51 48 53 51 50 49
Peripheral vascular disease 34 28 34 36 36 36
Cerebrovascular disease 28 23 28 29 30 29
Chronic pulmonary disease 38 32 39 39 39 42
Peptic ulcer disease 6 6 6 6 6 5
Diabetes 69 69 72 71 69 63
Liver disease 11 13 12 10 10 10
Cancer 22 21 22 22 22 22
Bleeding disorders 26 23 25 26 26 28
Initial access type, %
AV fistula/AV graft 22 18 22 27 25 17
Catheter 69 75 70 64 65 72
Other/unknown 9 7 8 9 11 11
6-Month averaged laboratory measures
Bicarbonate, mEq/L 23.0±4.0 21.4±3.9 22.4±3.7 22.8±3.7 23.4±3.9 24.7±4.0
Potassium, mEq/L 4.5±0.5 4.5±0.6 4.5±0.5 4.5±0.5 4.5±0.6 4.4±0.5
Blood urea nitrogen, mg/dL 62.5±23.4 71.7±25.3 66.3±21.4 64.5±21.4 60.3±21.6 49.4±23.3
White blood cell count, ×103/μL 7.8±3.1 7.7±3.8 7.8±3.3 7.7±2.7 7.7±2.8 8.2±3.1
Alkaline phosphatase, U/L 84 (66–110) 83 (64–109) 85 (66–112) 83 (65–109) 84 (66–110) 84 (67–109)
Albumin, g/dL 3.4±0.6 3.1±0.6 3.2±0.6 3.4±0.6 3.5±0.6 3.6±0.6
Calcium, mg/dL 8.7±0.7 8.3±0.8 8.5±0.7 8.7±0.7 8.9±0.7 9.0±0.7
Phosphorous, mg/dL 5.1±1.3 5.6±1.5 5.2±1.3 5.1±1.2 4.9±1.2 4.7±1.2
Ferritin, ng/mL 199 (106–367) 246 (122–447) 219 (116–398) 189 (104–338) 173 (96–311) 144 (82–285)
Body mass index, kg/m2 29.9±6.6 29.2±6.7 29.7±6.7 29.8±6.5 30.2±6.6 30.7±6.7
Systolic blood pressure, mm Hg 142±18 146±18 143±17 142±18 141±18 139±19
Diastolic blood pressure, mm Hg 74±11 75±12 73±11 73±11 74±12 75±12
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tions, this U-shaped relationship persisted but was slight-
ly attenuated for associations of higher Hgb with higher 
mortality risk. Hgb < 9 g/dL was associated with 25% 
higher mortality risk after full adjustment compared to 
Hgb 10–< 11 g/dL (HR [95% CI] 1.25 [1.15–1.35]). More-
over, in restricted cubic spline analysis, lower Hgb < 10 g/
dL was associated with higher mortality after full adjust-
ment, though higher Hgb ≥11 g/dL trended toward high-
er all-cause mortality risk (online suppl. Fig. S2a). Finally, 
low Hgb < 10 g/dL was associated with higher early all-
cause mortality across most strata of clinical characteris-
tics and laboratory measurements (ref: Hgb 10–< 11 g/
dL), while higher Hgb ≥11 g/dL trended toward higher 
mortality risk though attenuated in some strata (online 
suppl. Fig. S3). There were significant interactions on the 
basis of prior congestive heart failure, cerebrovascular 
disease, diabetes, and higher CCI ≥4, whereas lower Hgb 
< 10 g/dL was associated with a higher risk of mortality 
among patients without said comorbidities. There was no 
interaction on the basis of hematological conditions or 
use of ESA or iron medications.
Baseline Hgb concentrations also exhibited a similar 
U-shaped association with 12-month CV mortality af-
ter adjustment for clinical characteristics (online suppl. 
Table S1b; Fig. 1b). Patients with Hgb 11–< 12 and ≥12 
g/dL had the highest risk of early CV mortality (HR 
[95% CI] 1.29 [1.14–1.46] and 1.28 [1.12–1.45], respec-
tively), (ref: Hgb 10–< 11 g/dL). In restricted cubic 
spline analysis, continuous Hgb largely exhibited a U-
shaped relationship with CV mortality, though it was 
modestly attenuated after full adjustment (online suppl. 
Fig. S2b). 
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Fig. 1. Association of 6-month pre-end-stage renal disease (ESRD) hemoglobin (Hgb) with (a) 12-month all-cause mortality and (b) 
12-month cardiovascular mortality in 31,472 veterans transitioning to ESRD.
Total 6-Month pre-ESRD Hgb strata, g/dL
<9 9–<10 10–<11 11–<12 ≥12
Last eGFR prior to transition, mL/min/1.73 m2 9.7 (7.1–13.2) 8.4 (5.9–11.8) 9.4 (6.8–12.7) 9.6 (7.1–12.9) 10.1 (7.5–13.5) 10.9 (7.9–15.6)
Medication use in the 6 months prior to
transition, %
ESA 32 51 47 34 19 5
Iron 39 59 53 40 28 13
Data presented as mean ± SD, median (IQR), or proportion where appropriate.
ESRD, end-stage renal disease; Hgb, hemoglobin; AV, arteriovenous; eGFR, estimated glomerular filtration rate; ESA, erythropoietin stimulating agents; IQR, 
interquartile range.
Table 1. (continued)
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6-Month Averaged Pre-ESRD Hgb and 12-Month 
Post-ESRD Hospitalization
Overall, the patients had a median (IQR) of 1 (0–3) 
hospitalizations in the first 12 months after progression 
to ESRD. Across all levels of adjustment, compared to 
Hgb 10–< 11 g/dL, lower baseline Hgb levels (< 10 g/dL) 
were associated with higher hospitalization rates (online 
suppl. Table S2; Fig.  2). In contrast, higher Hgb levels 
(≥11 g/dL) were not associated with hospitalization inci-
dence. In this cohort, the most common cause (listed pri-
mary diagnosis) of hospitalization after transitioning to 
ESRD was dialysis access complications, where patients 
with Hgb < 9 g/dL had the highest rate of this diagnosis. 
Hospitalization rates for nonhypertensive congestive 
heart failure were highest among patients with Hgb ≥12 g/
dL (online suppl. Table S3). 
Hgb Trajectories Before and After ESRD Transition
In the prelude period, all baseline Hgb groups showed 
a gradual decreasing trend when approaching transition 
to ESRD (Fig. 3). However, patients with a lower prelude 
6-month averaged baseline Hgb (< 10 g/dL) had the steep-
est decline before ESRD initiation. Within the first few 
months after ESRD initiation, all Hgb groups were rap-
idly corrected toward 11–12 g/dL with a reduction in 
variation across groups in the post-ESRD period. Though 
the overall variations between the Hgb groups were vast-
ly attenuated after ESRD initiation, the hierarchical order 
was maintained through the first year of ESRD. 
12-Month Pre-ESRD Slope in Hgb and 12-Month 
Post-ESRD Mortality and Hospitalization
To further examine trajectories of pre-ESRD Hgb, 
slopes were calculated in 24,699 patients (78% of the base-
line cohort). The median (IQR) rate of change in pre-
ESRD Hgb was –1.6 (–2.6 to –0.7) g/dL/year. Patients 
with the steepest decline were younger, had a lower prev-
alence of comorbid conditions, including diabetes and 
congestive heart failure, had a steeper eGFR slope, and 
were less likely to be treated with ESA or iron (online 
suppl. Table S4).
After adjustment for clinical conditions, laboratory 
parameters and final Hgb, patients with the steepest Hgb 
decline (≤–3 g/dL/year) had the highest risk of 12-month 
all-cause mortality compared to a moderate decline in 
Hgb (>–2 to ≤–1 g/dL/year) (HR [95% CI] 1.10 [1.01–
1.19]; online suppl. Table S5a; Fig. 4a). However, this as-
sociation was attenuated to the null after additional ad-
justment for eGFR slope. A similar relationship was ob-
served between the Hgb slope and CV mortality. The 
steepest Hgb decline (≤–3 g/dL/year) was associated with 
the highest risk of CV mortality (HR [95% CI] 1.17 [1.01–
1.36]), yet this relationship was again attenuated after fur-
ther eGFR slope adjustment (online suppl. Table S5b; 
Fig. 4b). In restricted cubic spline analyses, the relation-
ship of Hgb slope with all-cause mortality showed a com-
parable attenuated relationship. However, the association 
between Hgb slope with CV mortality trended toward a 
U-shaped association, after full adjustment including 
eGFR slope (online suppl. Fig. S4a, b).
Finally, we observed a U-shaped association with Hgb 
slope and early post-ESRD hospitalization rate after ad-
justment for case-mix and MICS covariates (online suppl. 
Table S6; Fig.  5a). After further adjustment for eGFR 
slope, the association attenuated to a modest J-shape, 
where a steep decline in Hgb trended toward a higher 
hospitalization rate (incidence rate ratio [95% CI] 1.05 
[0.99–1.10]). However, a rise in Hgb was associated with 
a higher hospitalization incidence after full adjustment, 
compared to a moderate Hgb decline (>–2 to ≤–1 g/dL/
year; incidence rate ratio [95% Cl] 1.10 [1.04–1.16]).
Discussion
In our cohort of 31,472 veteran patients transitioning 
to ESRD, we observed a U-shaped association between 
pre-ESRD Hgb and 12-month post-ESRD all-cause and 
CV mortality, in which low Hgb < 9 g/dL and high Hgb 
≥12 g/dL demonstrate the highest risks. Moreover, lower 
6-Month pre-ESRD Hgb, g/dL
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Fig. 2. Association of 6-month pre-end stage renal disease (ESRD) 
hemoglobin (Hgb) with 12-month hospitalization count in 31,472 
veterans transitioning to ESRD. IRR, incidence rate ratio.
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pre-ESRD Hgb was associated with higher hospitaliza-
tion rates. However, neither a decline nor an increase in 
Hgb slope in the 1 year prior to transition to ESRD was 
associated with all-cause or CV mortality in the fully ad-
justed model, including adjustment for kidney function 
decline. Nevertheless, an increased Hgb slope in the 1 year 
prior to transition to ESRD was associated with higher 
hospitalization rates even after adjustment for eGFR 
slope. 
The association between anemia and adverse out-
comes has been well established. For instance, anemia is 
an independent risk factor for left ventricular hypertro-
phy, as well as morbidity and mortality from CV causes 
[25–27]. Although ESA therapy is indicated for anemia 
management, several clinical trials have suggested that 
treatment of anemia to “normalized” Hgb levels is associ-
ated with adverse outcomes in both dialysis and CKD pa-
tients [14, 28–30]. Therefore, current guidelines [5] ad-
vise against increasing Hgb levels above 13.0 g/dL. In the 
Correction of Hgb and Outcomes in Renal Insufficiency 
randomized clinical trial, non-dialysis dependent CKD 
patients reaching and maintaining Hgb concentrations of 
either 13.5 or 11.3 g/dL with epoetin alpha were com-
pared, and those randomized to the 13.5 g/dL group suf-
fered from more adverse events including death, myocar-
dial infarction, and hospitalization for congestive heart 
failure or stroke, compared to patients in the 11.3 g/dL 
arm [28]. In addition, a higher death risk for patients with 
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Hgb > 13.5 g/dL compared to 11.5–< 12.0 g/dL has also 
been observed in a large cohort of hemodialysis patients. 
However, the death risk was even higher for patients with 
Hgb < 10 g/dL when compared to 11.5–< 12.0 g/dL [17]. 
Therefore, it might be inferred that “too low” Hgb levels 
could impose greater harm to patients than “too high” 
Hgb concentrations. Similarly, our observational data 
showed that pre-ESRD Hgb levels had a modest U-shaped 
association with post-ESRD mortality outcomes, where 
patients with pre-ESRD Hgb concentrations < 9 g/dL had 
the highest all-cause and CV mortality risk and patients 
with Hgb values ≥12 g/dL had a modestly higher risk of 
all-cause and CV mortality when compared to the refer-
ence group (Hgb: 10–< 11 g/dL) in fully adjusted models. 
In our study, elevated pre-ESRD Hgb was not associated 
with higher hospitalization rates. However, when exam-
ining hospitalization causes, nonhypertensive congestive 
heart failure was more frequent in ESRD patients with 
prelude Hgb ≥12 g/dL. 
Kidney disease patients transitioning to dialysis-de-
pendent CKD have a particularly high mortality risk 
within the first 6 months after the initiation of dialysis 
treatment compared to prevalent HD patients or renal 
transplant recipients [18, 31, 32]. Therefore, specialized 
pre-ESRD patient care, which focuses on factors that are 
commonly associated with adverse clinical events may 
improve post-ESRD outcomes. Since anemia is common 
sequelae of advanced CKD, we examined the association 
between changes in Hgb with early-ESRD outcomes. In 
our study, on average most patients exhibited a decline in 
Hgb during the 1 year prelude (pre-ESRD) period. The 
latter observation may have several important underlying 
causes that need to be considered. For instance, a decreas-
ing Hgb slope may represent a faster decline in kidney 
function and/or deteriorating health status as CKD pro-
gresses. In addition, Hgb values are influenced by several 
different factors such as genetics [33], infection, inflam-
mation [34, 35], and acute and chronic comorbidities 
[36]. Furthermore, medications such as angiotensin-con-
verting enzyme inhibitors and angiotensin receptor 
blockers can also interfere with a patients’ responsiveness 
to ESA treatment and subsequently impact Hgb levels 
[37]. In our study, neither a decline nor rise in Hgb slope 
in the 1 year prior to transition to ESRD was associated to 
higher all-cause or CV mortality after adjustment for 
eGFR slope. 
However, a modest J-shaped association was observed 
between Hgb slope and higher hospitalization rates in ful-
ly adjusted models, where a rise in Hgb was associated 
with a 10% higher hospitalization incidence rate. Prior 
reviews have commented that increasing Hgb from ESA 
treatment results in increasing blood viscosity, resulting 
in increased viscosity-associated sheer stress, which in 
turn might then lead to thromboembolism [38, 39]. These 
factors may be of particular relevance in patients with 
CKD who are more likely to have atherosclerotic CV dis-
ease and a higher risk of poor CV outcomes. Although we 
adjusted for ESA and iron treatment in fully adjusted 
models, a residual effect of these therapies on Hgb and 
blood viscosity may further confound the association be-
tween Hgb rise and hospitalization. A decline in Hgb was 
associated with higher hospitalization rates but was at-
tenuated toward the null after adjustment for eGFR slope. 
As discussed above, Hgb decline may be related to a de-
teriorating health condition and consequent hospitaliza-
tions due to CKD progression. 
Strengths of our study include the large veteran popula-
tion size and ability to comprehensively capture data on 
comorbidity status and medication prescriptions in the 
pre-ESRD period. In addition, given the availability of re-
peated measures, we were able to calculate the change in 
Hgb prior to transition. However, several limitations of our 
study should be noted. First, due to the observational study 
design, we cannot make any decisive claims about the caus-
al associations between Hgb levels or the rate of Hgb change 
with mortality and hospitalizations. It is also important to 
note that we are unable to completely exclude sources of 
residual confounding by variables that were not measured 
and were not included in the analysis cohort such as in-
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flammatory status, number of blood transfusions, and fre-
quent acute events such as bleeding or hospitalization. 
Moreover, slopes were calculated using linearity assump-
tions and may be affected by acute episodes of anemia (e.g. 
blood loss, hospitalizations), which could also explain the 
observed associations. Given that the source population 
consisted of US veterans, and primarily Veteran Affairs us-
ers who are predominately white and male, this study may 
not be externally valid to other populations. 
In conclusion, we observed that both pre-ESRD Hgb 
<10 and ≥12 g/dL are associated with higher all-cause and 
CV mortality, and low Hgb is associated with higher hos-
pitalization rates. In our fully adjusted model, which in-
cluded eGFR slope, neither a decline nor increase of the 
Hgb slope was associated with all-cause or CV mortality. 
However, a rise in Hgb in the 1 year prior to transition to 
ESRD with adjustments for the last Hgb value and eGFR 
slope was associated with higher hospitalization rates. 
Thus, treatment of anemia and achieving and maintain-
ing an appropriate Hgb level prior to ESRD transition 
may be of value in improving early post-ESRD outcomes. 
Further studies are warranted to compare the effective-
ness of different anemia management strategies in the late 
stages of CKD in improving clinical outcomes in the post-
ESRD period.
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